Comparative Pharmacology
Head-to-head clinical analysis: AZACITIDINE versus INQOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACITIDINE versus INQOVI.
AZACITIDINE vs INQOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA methyltransferase, leading to hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in bone marrow. It incorporates into RNA and DNA, causing disruption of nucleic acid metabolism and apoptosis.
INQOVI is a combination of decitabine, a hypomethylating agent that inhibits DNA methyltransferase, and cedazuridine, a cytidine deaminase inhibitor that prevents degradation of decitabine, increasing its systemic exposure.
75 mg/m² subcutaneously or intravenously once daily for 7 days every 28 days.
INQOVI (decitabine and cedazuridine) is administered orally once daily on days 1 through 5 of a 28-day cycle. The recommended dose is 1 tablet (35 mg decitabine and 100 mg cedazuridine) taken on an empty stomach.
None Documented
None Documented
Clinical Note
moderateAzacitidine + Digoxin
"Azacitidine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAzacitidine + Digitoxin
"Azacitidine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAzacitidine + Deslanoside
"Azacitidine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAzacitidine + Acetyldigitoxin
"Azacitidine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 4 hours (subcutaneous or intravenous); reflects rapid deamination by cytidine deaminase.
The terminal elimination half-life of decitabine is approximately 2.5 hours (range 1.5-3.5 hours) following oral INQOVI administration. Cedazuridine has a similar half-life of about 2 hours. The half-lives are short, necessitating daily dosing for 5 days per cycle.
Renal (primarily as metabolites, ~50-85% of administered dose within 72 hours); fecal/biliary negligible.
Decitabine and cedazuridine are primarily excreted renally. Following oral administration, 58-64% of the decitabine dose and 93% of the cedazuridine dose are recovered in urine, with <2% in feces. Renal excretion is the main elimination pathway for both components.
Category C
Category C
Hypomethylating Agent
Hypomethylating Agent